The purpose of this study is to determine if remibrutinib is more effective than teriflunomide in reducing the frequency of relapses in people with relapsing forms of MS. Participants in the study will be randomly assigned to receive either remibrutinib, teriflunomide, or a placebo, which is a substance with no active medication. The study will begin with a period where participants receive either remibrutinib or teriflunomide, followed by an extended treatment phase where all participants will receive remibrutinib. This approach helps researchers understand the long-term effects of remibrutinib on MS.

Throughout the study, participants will take the medications orally, and their health will be monitored regularly to assess the impact of the treatments. The study aims to provide valuable information on how well remibrutinib works compared to teriflunomide and to ensure the safety of participants. By participating in this study, researchers hope to find a more effective treatment option for those living with relapsing MS.

The purpose of this study is to determine how safe and tolerable Tolebrutinib is over a long period. Participants will take the medication orally, and the study will last for up to 36 months. During this time, researchers will monitor participants for any adverse events, which are unwanted effects that may occur during the study. The study will also look at how the medication affects the progression of disability in participants with MS and track any changes in the brain using Magnetic Resonance Imaging (MRI), a type of scan that provides detailed images of the brain.

In addition to Tolebrutinib, the study involves other substances like Anhydrous Cholestyramine, which is used to bind certain substances in the intestines, and Magnetic Resonance Imaging Contrast Media, which helps improve the clarity of MRI images. These substances are used to support the study’s objectives and ensure accurate monitoring of the participants’ health. The study aims to provide valuable information on the long-term use of Tolebrutinib in managing Multiple Sclerosis.

The investigation is divided into two parts to compare different ways of giving the medication. One part looks at using different areas of the body for the injection, while the other part compares using an autoinjector, a device designed to deliver the medicine automatically, against a standard syringe. This comparison helps to determine the relative bioavailability, which refers to how much of the drug actually enters the bloodstream when using one method versus another.

The purpose of the study is to understand how ublituximab works in young people with this condition, to see if it works as well as fingolimod, and to check its safety over a long period of time. The study is divided into three parts. In the first part, researchers will examine how the body processes ublituximab and how it affects certain immune cells in participants aged 10 to under 18 years. In the second part, the study will compare how well ublituximab works against fingolimod in controlling the disease. In the third part, participants who completed earlier parts of the study can continue to receive ublituximab to help researchers learn about its long-term safety and effectiveness.

During the study, ublituximab will be given through an intravenous infusion, which means it will be delivered directly into a vein, while fingolimod is taken by mouth as a capsule. Participants will have regular check-ups where doctors will monitor their condition, perform brain scans using MRI (a type of imaging that creates detailed pictures of the brain), check blood cell counts, and watch for any side effects. The study will track whether participants experience relapses, which are periods when symptoms get worse, and will measure changes in brain lesions, which are areas of damage that can be seen on brain scans. Throughout the study, the medical team will carefully monitor each participant’s safety and response to treatment.

The main purpose of this research is to determine if remibrutinib is as effective as ocrelizumab in controlling disease activity as seen on magnetic resonance imaging (MRI) scans. The study will look at patients who are currently using ocrelizumab and switch them to either continue ocrelizumab or start taking remibrutinib. The study will track participants’ progress for 24 months to compare how well both treatments work.

During the study, participants will receive either remibrutinib tablets taken by mouth or ocrelizumab given through injection or infusion. Doctors will monitor participants’ health through regular check-ups and MRI scans to track any changes in their condition. After the initial 24-month comparison period, all participants will have the opportunity to receive remibrutinib for an extended period.

The purpose of this research is to compare two different ways of giving the same medicine: under the skin (subcutaneous injection) versus directly into a vein (intravenous administration). The study will examine how the body processes the medication when given through these different methods and evaluate its effects on disease symptoms.

During the study, participants will receive ublituximab either as an injection under the skin or through an intravenous infusion. The research team will monitor the participants’ response to treatment, including how well the medication is working and any side effects that may occur. The study will track changes in participants’ condition through various medical assessments and imaging tests.

Participants in the study will receive YTB323 through an intravenous infusion, which means the treatment is delivered directly into the bloodstream. In addition to YTB323, some participants may also receive other medications such as Tocilizumab, Cyclophosphamide, and Fludarabine Phosphate, which are commonly used in medical treatments to manage immune responses and support the main therapy. The study will monitor the participants over time to observe any changes in their condition and to ensure the treatment is safe.

The trial will also involve regular check-ups, including tests like MRI scans, to track the progress of the disease and the effects of the treatment. The study aims to gather information on how the treatment affects the body and how well it works in managing the symptoms of Relapsing Multiple Sclerosis. This information will help in understanding the potential benefits and risks of using YTB323 for this condition.

The purpose of the study is to evaluate how well this modified regimen of ublituximab works in reducing certain types of brain lesions, which are areas of damage in the brain that can be seen using a special imaging technique called MRI (magnetic resonance imaging). Participants in the study will receive the treatment over a period of 48 weeks, and the main goal is to see if there is no change or a reduction in the number of these lesions from the start of the study to the end. The study will also look at other aspects, such as the overall satisfaction of participants with the treatment and any side effects they may experience.

In addition to ublituximab, other medications like cetirizine, dexamethasone, methylprednisolone, paracetamol, diphenhydramine, and gadobutrol may be used during the study. These medications are commonly used to manage symptoms or as part of the treatment process. The study aims to provide valuable information on the effectiveness and safety of ublituximab for people with relapsing multiple sclerosis, potentially leading to improved treatment options in the future.

The purpose of the study is to assess how well Fenebrutinib works in reducing the number of new lesions in the brain, which are areas of damage that can be seen on an MRI scan. These lesions are a sign of disease activity in multiple sclerosis. The study will involve regular MRI scans at specific intervals to monitor the development of these lesions over time.

Participants will be monitored for any side effects and changes in their health throughout the study. The trial will also measure the concentration of Fenebrutinib in the blood at certain times to understand how the body processes the medication. The study aims to provide valuable information on the potential benefits of Fenebrutinib for people with relapsing multiple sclerosis.

The purpose of the study is to see if IMU-838 can delay the occurrence of relapses, which are episodes of new or worsening symptoms. Participants in the study will be randomly assigned to receive either the IMU-838 tablets or a placebo. The study is designed to be double-blinded, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not influenced by expectations about the treatment.

Throughout the study, participants will take the medication orally in tablet form. The study will monitor the time it takes for participants to experience their first confirmed relapse, as well as other factors like changes in brain lesions seen on MRI scans and any changes in disability levels. The study aims to provide valuable information about the potential benefits of IMU-838 for people with Relapsing Multiple Sclerosis.

During the study, participants will receive ublituximab and may also receive other medications such as methylprednisolone, cetirizine, paracetamol, diphenhydramine, dexamethasone, and sodium chloride. These medications are commonly used to manage symptoms or support the treatment process. The study will monitor how ublituximab is absorbed, distributed, and eliminated by the body, as well as its effects on certain immune cells called B-cells.

The trial will take place over several years, with participants attending regular visits to receive the medication and undergo assessments. These assessments will help researchers gather important information about the safety and effectiveness of ublituximab in treating these autoimmune conditions. The study aims to provide valuable insights that could improve treatment options for patients with Myasthenia Gravis and Relapsing Multiple Sclerosis.

Participants in this study will receive tolebrutinib, which is taken as a film-coated tablet, or a placebo. The study will also involve the use of another medication called Aubagio, which contains the active substance teriflunomide. Some participants may receive a placebo that matches the appearance of Aubagio. The study will monitor participants for any side effects or adverse events that may occur while taking these medications. Additionally, the study will track changes in the participants’ condition, such as the progression of disability or the rate of relapses in those with RMS.

The study will last for several years, allowing researchers to gather comprehensive data on the long-term effects of tolebrutinib. Participants will be regularly assessed to ensure their safety and to evaluate the effectiveness of the treatment. The study aims to provide valuable insights into the management of multiple sclerosis and to improve treatment options for those living with this condition.

Participants in the study will receive either the new treatment or a placebo. The treatment involves an injection, and the study will monitor the participants over a period to observe any changes in the number of new brain lesions. These lesions are detected using MRI scans, a type of imaging that helps doctors see inside the body without surgery. The study will help determine if LY3541860 is effective in reducing the occurrence of these lesions.

In addition to LY3541860, the study will also use Gadoteric Acid, a contrast agent used in MRI scans to improve the clarity of the images. This agent is injected into the body to help highlight certain areas during the scan. The study will provide valuable information on the safety and effectiveness of LY3541860 in treating relapsing multiple sclerosis.

The purpose of the study is to determine if remibrutinib is better than teriflunomide in reducing the number of relapses, which are periods when symptoms of multiple sclerosis suddenly get worse. The study will begin with a period where participants are randomly assigned to receive either remibrutinib or teriflunomide. After this initial phase, all participants will have the opportunity to receive remibrutinib for an extended period. This approach helps researchers understand the long-term effects of remibrutinib on multiple sclerosis.

Throughout the study, participants will take their assigned medication by mouth, and their health will be monitored regularly. This includes checking for any new symptoms, changes in their condition, and any side effects from the medication. The study aims to provide valuable information about how well remibrutinib works compared to teriflunomide and to ensure the safety of participants while they are taking these medications.

The trial is divided into two parts. In the first part, participants will receive BIIB091 by itself to assess its safety and how well it is tolerated. In the second part, participants will receive a combination of BIIB091 and Diroximel Fumarate, or Diroximel Fumarate alone, to compare the effects on brain inflammation as seen on MRI scans. MRI, or Magnetic Resonance Imaging, is a technique used to create detailed images of the organs and tissues in the body, which helps in monitoring the disease’s activity.

Participants in the study will be randomly assigned to different treatment groups, and the study will be conducted in a way that neither the participants nor the researchers know which treatment is being given, to ensure unbiased results. The study will last for a period of up to 48 weeks for each participant, during which they will receive regular check-ups and monitoring to ensure their safety and to gather data on the effectiveness of the treatments. The goal is to find a treatment that can help manage the symptoms of relapsing forms of Multiple Sclerosis more effectively.

Participants in the study will receive ublituximab, which is administered as a concentrate for solution for infusion, meaning it is given through a drip into a vein. The study will follow participants over a period to monitor their health and any changes in their condition. This includes tracking the number of relapses, changes in brain scans using MRI, and any progression or improvement in disability. The study will also assess cognitive function and overall safety, including any side effects experienced during the treatment.

Throughout the study, researchers will collect data on various health parameters to understand how well ublituximab works in managing relapsing multiple sclerosis and to ensure it is safe for long-term use. This information will help in determining the potential benefits and risks of using ublituximab as a treatment option for individuals with this form of MS.